Clinical Trials Pipeline & In-Development

Amycretin

also known as: NNC0487-0111

Novo Nordisk's unimolecular GLP-1 + amylin dual agonist — Phase 1b oral data published 2024 showed ~13% weight loss in 12 weeks; SC Phase 1b reported ~22% weight loss at 36 weeks in 2025. Phase 3 programs initiating 2026. Novo's answer to the retatrutide/triple-agonist class.

A novel unimolecular dual agonist at the GLP-1 and amylin receptors, developed by Novo Nordisk as a single-peptide combination of the two leading metabolic mechanisms (one of which, amylin, has been validated by pramlintide and is being independently pursued as cagrilintide and petrelintide); oral Phase 1b data in The Lancet in 2024 reported approximately 13% weight loss at 12 weeks, and subcutaneous Phase 1b data reported in 2025 reached approximately 22% at 36 weeks, positioning amycretin as Novo's leading late-stage response to the triple-agonist class.

Mechanism of action

A single peptide that activates both the GLP-1 receptor and the amylin receptor, combining the appetite-suppressant and gastric-emptying effects of GLP-1 agonism with the satiety, glucagon-suppression, and gastric-emptying effects of amylin agonism. The unimolecular approach mirrors the success of tirzepatide's GLP-1/GIP dual agonism in a single molecule rather than requiring a fixed-dose combination like CagriSema.

Primary uses

Chronic weight management (Phase 1b positive; Phase 3 initiating 2026)
Research into unimolecular multi-receptor agonism

Typical dosing

not finalized mg weekly (SC) or daily (oral) (subcutaneous or oral)

Phase 1b dosing data not fully disclosed; Phase 3 dose-ranging in progress.

Regulatory status

Not approved. Novo Nordisk is developing amycretin in both oral and subcutaneous formulations; Phase 3 programs are being initiated in 2026 following Phase 1b data.

References

[pubmed] Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management." Lancet, 2021;397:1736-1748. [context for Novo amylin programs]
[manufacturer] Novo Nordisk A/S. "Amycretin Phase 1b topline data announcements, 2024–2025," investor presentations.

Related peptides

CagriSema

Novo Nordisk's next-generation obesity injection — NDA filed December 2025, FDA review expected 2026. If approved, it would be the first GLP-1 + amylin fixed-dose combination and a direct competitive response to tirzepatide.

Petrelintide

Zealand Pharma's amylin monotherapy — ZUPREME-1 Phase 2b hit its endpoints in March 2026 with up to 10.7% weight loss at 42 weeks and "placebo-like" GI tolerability. Roche-partnered since 2025; Phase 3 planned for late 2026.

Orforglipron

⚠ Not a peptide — small molecule. A daily oral GLP-1 agonist in Phase 3 for obesity and T2DM, distinct from Rybelsus in being a small molecule rather than an oral peptide formulation. Included in this peptide encyclopedia because the audience frequently searches for it alongside peptide GLP-1 agonists.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.